US Drug Recall Register

FDA Drug Recalls

2,277 recalls · Class II, newest first

Class II · Moderate risk Ongoing

Levofloxacin Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0820-2023
Class II · Moderate risk Ongoing

Levofloxacin Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0819-2023
Class II · Moderate risk Ongoing

Levofloxacin Injection 500mg/20 mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0818-2023
Class II · Moderate risk Ongoing

Levocarnitine Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0817-2023
Class II · Moderate risk Ongoing

Levetiracetam Oral Solution 100 mg/mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0816-2023
Class II · Moderate risk Ongoing

Lactulose Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0815-2023
Class II · Moderate risk Ongoing

Lactulose Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0814-2023
Class II · Moderate risk Ongoing

Ketorolac Tromethamine Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0813-2023
Class II · Moderate risk Ongoing

IC-Green

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0812-2023
Class II · Moderate risk Ongoing

Hydromorphone Hydrochloride Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0811-2023
Class II · Moderate risk Ongoing

HydrALAZINE HCl Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0809-2023
Class II · Moderate risk Ongoing

Guaifenesin Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0808-2023
Class II · Moderate risk Ongoing

Guaiatussin AC Sugar-Free

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0807-2023
Class II · Moderate risk Ongoing

Granisetron HCl Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0806-2023
Class II · Moderate risk Ongoing

Fluticasone Propionate Nasal Spray

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0804-2023
Class II · Moderate risk Ongoing

Ferrous Sulfate Iron Supplement Drops

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0803-2023
Class II · Moderate risk Ongoing

Ephedrine Sulfate Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0802-2023
Class II · Moderate risk Ongoing

Docu Liquid

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0801-2023
Class II · Moderate risk Ongoing

Diuril

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0800-2023
Class II · Moderate risk Ongoing

Dicyclomine Hydrochloride Injection USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0799-2023
Class II · Moderate risk Ongoing

DetomiSed

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0798-2023
Class II · Moderate risk Ongoing

Cromolyn Sodium Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0797-2023
Class II · Moderate risk Ongoing

Clobetasol Propionate Shampoo

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0796-2023